ILMN vs DGX — Key Metrics
| Metric | ILMN (ILLUMINA INC) | DGX (QUEST DIAGNOSTICS INC) |
|---|---|---|
| Price | 210.01 | 259.69 |
| Market Cap | 31.75 Billion | 28.57 Billion |
| P/E (TTM) | 35.72 | 25.51 |
| P/B (Quarterly) | 11.346 | 3.487 |
| P/S (TTM) | 7.0 | 2.41 |
| Net Profit Margin (TTM) | 19.7 | 9.5 |
| Gross Margin (TTM) | 67.9 | 33.1 |
| ROE (TTM) | 31.5 | 15.2 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Outperform
Underperform
Recommendation Summary
Stock ILMN is projected to outperform the market, stock DGX is projected to underperform the market. Upfront Recommendation: ILMN.
Financial Metrics
| ILMN | Metrics | DGX |
|---|---|---|
| $210.01 | Price | $259.69 |
| — | Market Capitalization | — |
| 35.72 | Price to Earnings Ratio | 25.51 |
| 7.0 | Price to Sales | 2.41 |
| 30.04 | Price to FCF Ratio | 20.78 |
| 10.31 | Price to Gross Profit | 7.29 |
| 10.46 | Price to Current Assets | 9.17 |
ILMN vs DGX at a glance
Illumina INC (ILMN) and Quest Diagnostics INC (DGX) are both Diagnostics & Research companies in the Healthcare sector. They are similar in size: $31.8 billion and $28.6 billion in market value.
On trailing-twelve-month figures, ILMN trades at 35.7 times trailing earnings and DGX at 25.5; net profit margins are 19.7% and 9.5%.
The Upfront Investment model currently rates ILMN Outperform and DGX Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.